The Cancer Twins
Two sisters living with an exceptionally rare growth disorder have become part of a much larger scientific question: what if one of the most useful ways to understand cancer is to study human bodies in which some of the biological conditions cancer exploits have been altered from birth? The condition is Laron syndrome, a form of growth-hormone insensitivity caused by dysfunction of the growth-hormone receptor. The resulting biology includes extremely low levels of insulin-like growth factor 1, or IGF-1, an important regulator of growth, metabolism, and cellular activity. Researchers studying people with Laron syndrome, particularly a distinctive cohort in Ecuador, have repeatedly reported unusually low incidences of cancer and diabetes compared with relatives and wider populations. The finding has attracted scientific attention for decades. But “The Cancer Twins” must resist the temptation that makes the story irresistible online. Laron syndrome does not establish human immunity from cancer. Cancer has occurred within the Ecuadorian population, and the evidence concerns substantially diminished incidence, not biological invulnerability. A 2023 review of the Ecuadorian cohort explicitly documented cancer cases while maintaining the larger finding of unusually low cancer incidence. The more consequential proposition lies underneath the headline. Cancer requires more than mutations. Malignant cells must obtain signals, energy, metabolic support, opportunities to proliferate, and mechanisms for avoiding destruction. By studying people whose growth-signalling architecture differs markedly from the norm, researchers may gain an unusual natural experiment into the conditions that make malignant growth easier — or harder. The twins, then, are not scientific curiosities. Nor are they miracle patients. They represent something more intellectually valuable: a human biological exception capable of revealing the rules governing the rest of us.
